Pellegrino, ; Bella, ; Michiara, ; Zanelli, ; Naldi, ; Porzio, ; Bortesi, ; Boggiani, ; Zanoni, ; Camisa, ; Neri, ; T., M.; Pinto, ; Musolino, A, Triple negative status and BRCA mutations in contralateral breast cancer: A population-based study, «ACTA BIO-MEDICA DE L'ATENEO PARMENSE», 2016, 6, pp. 54 - 63 [articolo]
Guarneri, V.; Dieci, M. V.; Frassoldati, A.; Maiorana, A.; Ficarra, G.; Bettelli, S.; Tagliafico, E.; Bicciato, S.; Generali, D. G.; Cagossi, K.; Bisagni, G.; Sarti, S.; Musolino, A.; Ellis, C.; Crescenzo, R.; Conte, P., Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer, «THE ONCOLOGIST», 2015, 20, pp. 1001 - 1010 [articolo]
Buti, Sebastiano; Bersanelli, Melissa; Tiseo, Marcello; Ardizzoni, Andrea; Musolino, Antonino, BOLERO-3 results: Pharmacological activity or pharmacokinetic effect?, «THE LANCET ONCOLOGY», 2014, 15, pp. e304 - e304 [articolo]
Negri, F.V; Musolino, A.; Naldi, N.; Bortesi, B.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Chernyschova, N.; Bisagni, G.; Loupakis, F.; Ruzzo, A.; Neri, T.M.; Ardizzoni, A., Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy, «PHARMACOGENOMICS JOURNAL», 2014, 14, pp. 14 - 19 [articolo]
Bisagni, G; Musolino, A.; Panebianco, M.; De Matteis, A.; Nuzzo, F.; Ardizzoni, A.; Gori, S.; Gamucci, T.; Passalacqua, R.; Gnoni, R.; Moretti, G.; Boni, C., The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer, «CANCER CHEMOTHERAPY AND PHARMACOLOGY», 2013, 71, pp. 1051 - 1057 [articolo]
Musolino, Antonino; Michiara, Maria; Conti, Giovanni Maria; Boggiani, Daniela; Zatelli, Marella; Palleschi, Dario; Bella, Maria Angela; Sgargi, Paolo; Di Blasio, Beatrice; Ardizzoni, Andrea, Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study, «JOURNAL OF CLINICAL ONCOLOGY», 2012, 30, pp. 2362 - 2368 [articolo]
Guarneri, V.; Frassoldati, A.; Bottini, A.; Cagossi, K.; Bisagni, G.; Sarti, S.; Ravaioli, A.; Cavanna, L.; Giardina, G.; Musolino, A.; Untch, M.; Orlando, L.; Artioli, F.; Boni, C.; Generali, D. G.; Serra, P.; Bagnalasta, M.; Marini, L.; Piacentini, F.; D'Amico, R.; Conte, P., Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study, «JOURNAL OF CLINICAL ONCOLOGY», 2012, 30, pp. 1989 - 1995 [articolo]
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A, Activity and Safety of Dose-Adjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Non-Hodgkin Lymphoma, «CANCER», 2011, 117, pp. 964 - 973 [replica/breve intervento]
Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A, Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study, «CANCER», 2011, 117, pp. 1837 - 1846 [replica/breve intervento]
Boggiani D; Musolino A; Panebianco M; Franciosi V; Vasini G; Salvagni S; Ardizzoni A, ACTIVITY AND SAFETY OF DOSE-ADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DA-POCH-R) IN VERY ELDERLY PATIENTS WITH POOR-PROGNOSTIC UNTREATED DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA, «ANNALS OF ONCOLOGY», 2010, 21, pp. 352 - 352 [abstract]
Musolino, A; Guazzi, A; Nizzoli, R; Panebianco, M; Mancini, C; Ardizzoni, A, Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma, «TUMORI», 2010, 96, pp. 24 - 27 [articolo]
Musolino A; Michiara M; Conti GM; Boggiani D; Bozzani F; Zatelli M; Sgargi P; Ardizzoni A, HER2 STATUS AS PREDICTOR OF MAMMOGRAPHIC SCREENING DETECTION: COMPARISON OF INTERVAL- AND SCREEN-DETECTED BREAST CANCERS, «ANNALS OF ONCOLOGY», 2010, 21, pp. 78 - 79 [replica/breve intervento]
A. Musolino; M. Panebianco; E. Zendri; M Santini; S. Di Nuzzo; Ardizzoni A, Hypertriglyceridaemia with bexarotene in cutaneos T cell Lymphoma: the role of Omega-3 fatty acids, «BRITISH JOURNAL OF HAEMATOLOGY», 2009, 145, pp. 84 - 86 [replica/breve intervento]
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer, «JOURNAL OF CLINICAL ONCOLOGY», 2008, 26, pp. 1789 - 1796 [replica/breve intervento]
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A, BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study, «THE BREAST», 2007, 16, pp. 280 - 292 [replica/breve intervento]
